Alkem Laboratories Limited (NSE:ALKEM)
4,768.90
+136.40 (2.94%)
Mar 12, 2025, 9:30 AM IST
Alkem Laboratories Revenue
Alkem Laboratories had revenue of 33.74B INR in the quarter ending December 31, 2024, with 1.52% growth. This brings the company's revenue in the last twelve months to 127.57B, up 0.97% year-over-year. In the fiscal year ending March 31, 2024, Alkem Laboratories had annual revenue of 126.68B with 9.21% growth.
Revenue (ttm)
127.57B
Revenue Growth
+0.97%
P/S Ratio
4.48
Revenue / Employee
7.32M
Employees
17,432
Market Cap
571.25B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 126.68B | 10.68B | 9.21% |
Mar 31, 2023 | 115.99B | 9.65B | 9.08% |
Mar 31, 2022 | 106.34B | 17.69B | 19.96% |
Mar 31, 2021 | 88.65B | 5.21B | 6.24% |
Mar 31, 2020 | 83.44B | 9.87B | 13.42% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Zydus Lifesciences | 222.47B |
Apollo Hospitals Enterprise | 211.46B |
Aurobindo Pharma | 309.22B |
Fortis Healthcare | 75.61B |
Alkem Laboratories News
- 13 days ago - Nomura upgrades Alkem Labs to Buy and believes that concerns around growth are in price - Business Upturn
- 4 weeks ago - Alkem Laboratories Ltd (BOM:539523) Q3 2025 Earnings Call Highlights: Strategic Acquisitions ... - GuruFocus
- 4 weeks ago - Q3 2025 Alkem Laboratories Ltd Earnings Call Transcript - GuruFocus
- 4 weeks ago - Alkem Laboratories acquires 100% stake in Adroit Biomed for Rs 140 crore - Business Upturn
- 4 weeks ago - Alkem Laboratories shares drop 3% as revenue growth remains flat at Rs 3374 crore in Q3 - Business Upturn
- 4 weeks ago - Alkem Laboratories Q3 FY25 Results: Revenue flat at Rs 3374 crore, Profit up 6% YoY - Business Upturn
- 5 weeks ago - Alkem Laboratories launches Kojiglo serum for facial hyperpigmentation in India - Business Upturn
- 7 weeks ago - Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84% - Business Upturn